In This Article:
-
Kezar Life Sciences Inc (NASDAQ: KZR) announced topline results from the PRESIDIO Phase 2 trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM), chronic inflammatory diseases of muscle.
-
Topline results showed that most DM and PM patients saw clinically meaningful improvements in Total Improvement Score (TIS), but zetomipzomib demonstrated no significant differentiation from placebo.
-
At Week 16, the zetomipzomib 45 mg subcutaneously weekly group achieved a mean TIS of 25.5 versus the control group's mean TIS of 25.
-
Related: Small-cap Biopharma Kezar Life Sciences Is Soaring, Here's Why.
-
Following crossover, at week 32, the arm receiving zetomipzomib beginning at Week 16 achieved a mean TIS of 32.5 versus the control group's mean TIS of 31.3.
-
Zetomipzomib was well tolerated. Adverse events were generally mild-to-moderate, and the most common treatment-emergent adverse events were injection site reactions, which were transient and manageable.
-
One subject withdrew from the study following an injection site reaction.
-
There were three Grade 3 serious adverse events in the zetomipzomib arms, including one patient who experienced a mechanical fall and syncope and another patient who had a retinal detachment. All deemed unrelated to zetomipzomib.
-
Price Action: KZR shares closed 24.1% lower at $9.35 during after-hours trading on Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - joinBenzinga Profor free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.